Each filer's latest filing for 603170101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Catalys Pacific Fund, LP
13G/A
|
10.1% |
2/13/2026
Event 12/31/2025
|
||
| Catalys Pacific Fund, LP | 10.1% | |||
| Catalys Pacific Fund GP, LP | 10.1% | |||
| Catalys Pacific, LLC | 10.1% | |||
| Brian Taylor Slingsby | 10.1% | |||
|
RA Capital Management, L.P.
13D/A
|
9.9% |
9/8/2025
Event 9/4/2025
|
||
| RA Capital Management, L.P. | 9.9% | |||
| Peter Kolchinsky | 9.9% | |||
| Rajeev Shah | 9.9% | |||
| RA Capital Healthcare Fund, L.P. | 7.5% | |||
|
Samsara BioCapital, L.P.
13D/A
|
8.2% |
9/8/2025
Event 9/4/2025
|
||
| Samsara BioCapital, L.P. | 7.3% | |||
| Samsara BioCapital GP, LLC | 7.3% | |||
| Samsara Opportunity Fund, L.P. | 0.8% | |||
| Samsara Opportunity Fund GP, LLC | 0.8% | |||
| Srinivas Akkaraju | 8.2% | |||
| BlackRock, Inc. 13G | 5.2% |
1/21/2026
Event 12/31/2025
|
||
|
FMR LLC
13G/A
|
5.1% |
8/6/2026
Event 6/30/2026
|
||
| FMR LLC | 5.1% | |||
| Abigail P. Johnson | 5.1% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Andera Partners
13G/A
|
4.2% |
8/14/2025
Event 6/30/2025
|
||
| Andera Partners | 4.2% | |||
| BioDiscovery 6 FPCI | 4.2% | |||
| Stephane Bergez | 4.2% | |||
| Francois Xavier Mauron | 4.2% | |||
|
Adams Street Partners, LLC
13G/A
|
2.3% |
2/14/2025
Event 12/31/2024
|
||
| Adams Street Partners, LLC | 2.3% | |||
| Adams Street 2016 Direct Venture/Growth Fund LP | 0.2% | |||
| Adams Street 2017 Direct Venture/Growth Fund LP | 0.2% | |||
| Adams Street 2018 Direct Venture/Growth Fund LP | 0.4% | |||
| Adams Street 2019 Direct Growth Equity Fund LP | 0.2% | |||
| Adams Street 2020 Direct Growth Equity Fund LP | 0.2% | |||
| Adams Street 2021 Direct Growth Equity Fund LP | 0.2% | |||
| Adams Street Growth Equity Fund VII LP | 0.9% | |||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 220 | 97.0 M | $2.42B |
| 2026 Q2 | 227 | 99.7 M | $2.69B |
| 2026 Q1 | 218 | 90.3 M | $2.46B |
| 2025 Q4 | 228 | 88.4 M | $3.21B |
| 2025 Q3 | 195 | 79.3 M | $3.01B |
| 2025 Q2 | 169 | 65.7 M | $889M |
| 2025 Q1 | 157 | 61.2 M | $971M |
| 2024 Q4 | 111 | 46.5 M | $572M |
| 2024 Q3 | 107 | 44.4 M | $540M |
| 2024 Q2 | 95 | 44.2 M | $517M |
| 2024 Q1 | 93 | 41.9 M | $540M |
| 2023 Q4 | 88 | 34.7 M | $299M |
| 2023 Q3 | 78 | 26.5 M | $252M |
| 2023 Q2 | 69 | 25.2 M | $429M |
| 2023 Q1 | 67 | 24.6 M | $385M |